<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317575</url>
  </required_header>
  <id_info>
    <org_study_id>15645</org_study_id>
    <secondary_id>I8B-FW-ITRA</secondary_id>
    <nct_id>NCT02317575</nct_id>
  </id_info>
  <brief_title>A Study of LY900014 Formulations in Healthy Participants</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Glucodynamics of Multiple LY900014 Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates four test formulations of a glucose lowering drug (LY900014)
      administered by injection under the skin of the abdomen. The study will be conducted in
      healthy people to investigate how the human body handles LY900014 and the effect of LY900014
      on blood sugar levels. Side effects and tolerability will be documented. The study will be
      conducted in two parts (Part A and Part B) to achieve its objectives. Each part of the study
      will last for about 11 to 12 weeks, including screening and follow up. Screening is required
      within 28 days prior to entering into either study Part A or Part B.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Part A and Part B) Pharmacokinetics : Area under the Concentration Curve (AUC) of LY900014</measure>
    <time_frame>Predose through 5 hours postdose in each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Part A): Visual Analog Scale (VAS) Score for Injection Site Pain</measure>
    <time_frame>Predose through 5 hours postdose in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part A): Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp</measure>
    <time_frame>Predose through 5 hours postdose in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part B) Total Amount of Glucose Infused (Gtot) Over the Duration of the Clamp - Interparticipant Variability</measure>
    <time_frame>Predose through 5 hours postdose in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part B) Total Amount of Glucose Infused (Gtot) Over the Duration of the Clamp - Intraparticipant Variability</measure>
    <time_frame>Predose through 5 hours postdose in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part B): Pharmacokinetics: Area under the Concentration Curve (AUC) of LY900014 - Interparticipant Variability</measure>
    <time_frame>Predose through 5 hours postdose in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part B): Pharmacokinetics: Area under the Concentration Curve (AUC) of LY900014 - Intraparticipant Variability</measure>
    <time_frame>Predose through 5 hours postdose in each period</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A:LY900014 (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation A. Single dose of LY900014 administered subcutaneously (SC) in one of five periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:Insulin Lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference formulation. Single dose of insulin lispro administered SC in one of five periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:LY900014 (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation B. Single dose of LY900014 administered SC in one of five periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:LY900014 (C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation C. Single dose of LY900014 administered SC in one of five periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:LY900014 (D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation D. Single dose of LY900014 administered SC in one of five periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B:LY900014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation selected from Part A. Single dose of LY900014 administered SC in one of four periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY900014</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Part A:LY900014 (A)</arm_group_label>
    <arm_group_label>Part A:LY900014 (B)</arm_group_label>
    <arm_group_label>Part A:LY900014 (C)</arm_group_label>
    <arm_group_label>Part A:LY900014 (D)</arm_group_label>
    <arm_group_label>Part B:LY900014</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Part A:Insulin Lispro</arm_group_label>
    <other_name>Humalog</other_name>
    <other_name>LY275585</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy male or a female (not pregnant and agreeable to take birth control
             measures until one month after study completion)

          -  Have a body mass index (BMI) of 18.5 to 30 kilogram per square meter (kg/m^2),
             inclusive, at screening

          -  Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine
             laboratory test results that are acceptable for the study

          -  Are nonsmokers, have not smoked for at least 2 months prior to entering the study, and
             agree not to smoke (cigars, cigarettes, or pipes) or use smokeless tobacco for the
             duration of the study

        Exclusion Criteria:

          -  Are currently participating in or completed a clinical trial within the last 30 days
             from a clinical trial or any other type of medical research judged to be incompatible
             with this study

          -  Have previously participated or withdrawn from this study

          -  Have or used to have health problems or laboratory test results or ECG readings that,
             in the opinion of the doctor, could make it unsafe to participate, or could interfere
             with understanding the results of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2014</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

